News Releases

23 Feb '24
SIMLANDI is t he first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S . SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market SIMLANDI will qualify for interchangeab le exclusivity in
24 Jan '24
Attached is a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons. Alvotech Investor Relations Benedikt Stefansson, Senior Director Attachment Managers Transaction-CSSF Form -
21 Nov '23
REYKJAVIK, ICELAND, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first nine months of 2023, after U.S.
Displaying 1 - 10 of 140